TY - JOUR
T1 - A novel PAK1 variant causative of neurodevelopmental disorder with postnatal macrocephaly
AU - Ohori, Sachiko
AU - Mitsuhashi, Satomi
AU - Ben-Haim, Revital
AU - Heyman, Eli
AU - Sengoku, Toru
AU - Ogata, Kazuhiro
AU - Matsumoto, Naomichi
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to The Japan Society of Human Genetics.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - p21-activated kinases (PAKs) are protein serine/threonine kinases stimulated by Rho-family p21 GTPases such as CDC42 and RAC. PAKs have been implicated in several human disorders, with pathogenic variants in PAK3 associated with intellectual disability and several PAK members, especially PAK1 and PAK4, overexpressed in human cancer. Recently, de novo PAK1 variants were reported to be causative of neurodevelopmental disorder (ND) with secondary macrocephaly in three patients. We herein report a fourth patient with ND, epilepsy, and macrocephaly caused by a de novo PAK1 missense variant. Two previously reported missense PAK1 variants functioned as activating alleles by reducing PAK1 homodimerization. To examine the pathogenicity of the identified novel p.Ser110Thr variant, we carried out in silico structural analysis. Our findings suggest that this variant also prevents PAK1 homodimerization, leading to constitutive PAK1 activation.
AB - p21-activated kinases (PAKs) are protein serine/threonine kinases stimulated by Rho-family p21 GTPases such as CDC42 and RAC. PAKs have been implicated in several human disorders, with pathogenic variants in PAK3 associated with intellectual disability and several PAK members, especially PAK1 and PAK4, overexpressed in human cancer. Recently, de novo PAK1 variants were reported to be causative of neurodevelopmental disorder (ND) with secondary macrocephaly in three patients. We herein report a fourth patient with ND, epilepsy, and macrocephaly caused by a de novo PAK1 missense variant. Two previously reported missense PAK1 variants functioned as activating alleles by reducing PAK1 homodimerization. To examine the pathogenicity of the identified novel p.Ser110Thr variant, we carried out in silico structural analysis. Our findings suggest that this variant also prevents PAK1 homodimerization, leading to constitutive PAK1 activation.
UR - http://www.scopus.com/inward/record.url?scp=85078908298&partnerID=8YFLogxK
U2 - 10.1038/s10038-020-0728-8
DO - 10.1038/s10038-020-0728-8
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 32005903
AN - SCOPUS:85078908298
SN - 1434-5161
VL - 65
SP - 481
EP - 485
JO - Journal of Human Genetics
JF - Journal of Human Genetics
IS - 5
ER -